{"id":3969,"date":"2021-06-02T15:41:50","date_gmt":"2021-06-02T14:41:50","guid":{"rendered":"https:\/\/ibb.uab.cat\/?p=3969"},"modified":"2021-06-02T15:48:42","modified_gmt":"2021-06-02T14:48:42","slug":"novel-nano-encapsulation-approach-for-efficient-dopamine-delivery-in-parkinsons-treatment","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2021\/06\/02\/novel-nano-encapsulation-approach-for-efficient-dopamine-delivery-in-parkinsons-treatment\/","title":{"rendered":"Novel nano-encapsulation approach for efficient dopamine delivery in Parkinson\u2019s treatment"},"content":{"rendered":"\n

In a study just published in \u201cACS Nano\u201d, polymeric nanoparticles inspired by natural neuromelanin were used to encapsulate dopamine and to be administered via intranasal to reach the brain for Parkinson\u2019s disease treatment. This work was coordinated by ICN2 Group Leader Dr Daniel Ruiz-Molina\u00a0and Dr Julia Lorenzo, Group Leader at the Institute of Biotechnology and Biomedicine (IBB) of UAB, and\u00a0developed in collaboration with the group led by Prof. Miquel Vila\u00a0at\u00a0VHIR.<\/em><\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

In a study just published in \u201cACS Nano\u201d, polymeric nanoparticles inspired by natural neuromelanin were used to encapsulate dopamine and to be administered via intranasal to reach the brain for Parkinson\u2019s disease treatment. This work was coordinated by ICN2 Group Leader Dr Daniel Ruiz-Molina\u00a0and Dr Julia Lorenzo, Group Leader at the Institute of Biotechnology and Biomedicine (IBB) of UAB, and\u00a0developed in collaboration with the group led by Prof. Miquel Vila\u00a0at\u00a0VHIR.<\/em><\/strong><\/p>\n\n\n\n

However, dopamine is not directly administered, because it is unable to cross the so called blood-brain barrier<\/em>, which prevents some of the substances circulating in the blood to penetrate into the nervous system. Thus, DA precursor levodopa<\/em> (L-DOPA) \u2013an amino-acid which participates in the synthesis of dopamine\u2013 is used, due to its better ability to cross such barrier. Nevertheless, long-term and intermittent administration of this drug is associated with important disabling complications, such as motor disorders and involuntary muscle movements.<\/p>\n\n\n\n

In a paper<\/a> recently published in the American Chemical Society\u2019s Journal ACS Nano<\/em>, synthetic melanin-like nanoparticles are used to overcome these limitations. This research was coordinated by Dr Daniel Ruiz-Molina<\/strong>, leader of the ICN2 Nanostructured and Functional Materials Group, and Dr Julia Lorenzo<\/strong>, leader of the Protein Engineering Group at the Institute of Biotechnology and Biomedicine (IBB) of the Universitat Aut\u00f2noma de Barcelona (UAB), and was developed in collaboration with the Neurodegenerative Diseases group of Vall d\u2019Hebron Research Institute (VHIR), led by Prof. Miquel Vila<\/strong>.<\/p>\n\n\n\n

The main objective of this work was to obtain a \u201cnanoplatform\u201d \u2013which is a biocompatible nano-structure including the substance to be delivered\u2013 able to reach the brain through a noninvasive route and generate a slow and controlled release of dopamine. A tailor-made nanoscale coordination polymer<\/strong> (NCP), characterized by the reversible incorporation of DA as its principal component, was tested in vitro<\/em> and in vivo<\/em> in rats. Intranasal administration of these nanoparticles, called DA-NCPs, showed a relevant biocompatibility, non-toxicity and a fast and efficient distribution of dopamine in the central nervous system of the animals (avoiding the blood-brain barrier).<\/p>\n\n\n\n

As reported by the researchers, the proposed method is effective in delivering dopamine to the brain<\/strong> and<\/strong>, thus, in reversing Parkinson\u2019s symptoms<\/strong>. In addition, the synthetic methodology used is simple, cheap and exhibited a satisfactory yield (with a DA loading efficiency up to 60%).<\/p>\n\n\n\n

These findings establish nanoscale coordination polymers as promising future candidates for efficient nasal delivery of drugs to the central nervous system, and thus for the symptomatic treatment of people affected by Parkinson\u2019s and other neurodegenerative disorders. This type of nano-formulation and administration route may also pave the way to the development of other platforms able to deliver a wide range of drugs into the brain in a controlled manner, for the treatment of various brain diseases (such as brain tumours, Alzheimer\u2019s, Epilepsy).<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Reference article:<\/p>\n\n\n\n

Javier Garc\u00eda-Pardo, Fernando Novio, Fabiana Nador, Ivana Cavaliere, Salvio Su\u00e1rez-Garc\u00eda, Silvia Lope-Piedrafita, Ana Paula Candiota, Jordi Romero-Gimenez, Beatriz Rodr\u00edguez-Galv\u00e1n, Jordi Bov\u00e9, Miquel Vila, Julia Lorenzo, and Daniel Ruiz-Molina. Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson\u2019s Disease<\/strong>. ACS Nano<\/em> 2021, 15, 5, 8592\u20138609, May 2021. DOI: 10.1021\/acsnano.1c00453.<\/p>\n","protected":false},"excerpt":{"rendered":"

In a study just published in \u201cACS Nano\u201d, polymeric nanoparticles inspired by natural neuromelanin were used to encapsulate dopamine and to be administered via intranasal to reach the brain for Parkinson\u2019s disease treatment. This work was coordinated by ICN2 Group Leader Dr Daniel Ruiz-Molina\u00a0and Dr Julia Lorenzo, Group Leader at the Institute of Biotechnology and […]<\/p>\n","protected":false},"author":65,"featured_media":3970,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3969"}],"collection":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/comments?post=3969"}],"version-history":[{"count":1,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3969\/revisions"}],"predecessor-version":[{"id":3972,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3969\/revisions\/3972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media\/3970"}],"wp:attachment":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media?parent=3969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/categories?post=3969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/tags?post=3969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}